NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy

被引:1
|
作者
Dal Bello, Simone [1 ]
Lorenzut, Simone [2 ]
Saccomano, Emma [1 ]
Tereshko, Yan [1 ]
Gigli, Gian Luigi [3 ]
Pucillo, Carlo Ennio [4 ]
Valente, Mariarosaria [1 ,3 ]
机构
[1] Santa Maria Misericordia Univ Hosp, Clin Neurol Unit, I-33100 Udine, Italy
[2] Santa Maria Misericordia Univ Hosp, Neurol Unit, I-33100 Udine, Italy
[3] Univ Udine, Dept Med DMED, Neurol Unit, I-33100 Udine, Italy
[4] Univ Udine, Dept Med DMED, Immunol, I-33100 Udine, Italy
关键词
multiple sclerosis; Ocrelizumab; Rituximab; anti-CD20; NK cells;
D O I
10.3390/ph17020150
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Recently, research on the pathogenesis of multiple sclerosis (MS) has focused on the role of B lymphocytes and the possibility of using specific drugs, such as Ocrelizumab and Rituximab, directed toward these cells to reduce inflammation and to slow disease progression. Objective: We aimed to evaluate the effect of Ocrelizumab/Rituximab on laboratory immune parameters and identify the predictors of treatment responses. Methods: A retrospective single-center study was conducted among patients who received infusion therapy with an anti-CD20 drug to treat MS. Results: A total of 64 patients met the inclusion criteria, with 277 total cycles of therapy studied. Compared with the baseline values, anti-CD20 infusions resulted in absolute-value and percentage decreases in B lymphocyte levels and increased the absolute and percentage levels of NK cells 3 and 5 months after therapy (p < 0.001). After multivariate logistic regression analysis, a reduced percentage level of NK cells 3 months after infusion could predict disease activity 6 months after Ocrelizumab/Rituximab administration (p = 0.041). Conclusions: Lower percentage levels of NK cells 3 months after anti-CD20 infusion correlate with the presence of disease activity 6 months after therapy, confirming a possible protective role of NK cells in MS.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis
    Coerver, E.
    Schoof, L.
    Hogenboom, L.
    Wessels, M.
    van Ruyven, P.
    van Samkar, A.
    Mostert, J.
    van Kempen, Z.
    van Oosten, B. W.
    Wokke, B. H.
    Tallantyre, E.
    Myhr, K. M.
    Torkildsen, O.
    Killestein, J.
    Smets, I.
    Strijbis, E.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [2] Ocrelizumab: a B-cell depleting therapy for multiple sclerosis
    Jakimovski, Dejan
    Weinstock-Guttman, Bianca
    Ramanathan, Murali
    Kolb, Channa
    Hojnacki, David
    Minagar, Alireza
    Zivadinov, Robert
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (09) : 1163 - 1172
  • [3] Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis
    Capasso, Nicola
    Nozzolillo, Agostino
    Scalia, Giulia
    Lanzillo, Roberta
    Carotenuto, Antonio
    De Angelis, Marcello
    Petruzzo, Martina
    Sacca, Francesco
    Russo, Cinzia Valeria
    Morra, Vincenzo Brescia
    Moccia, Marcello
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 49
  • [4] A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis
    Evertsson, Bjorn
    Hoyt, Tammy
    Christensen, Angel
    AL Nimer, Faiez
    Foley, John
    Piehl, Fredrik
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2020, 6 (04)
  • [5] Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis
    Venet, Melany
    Lepine, Anne
    Maarouf, Adil
    Biotti, Damien
    Boutiere, Clemence
    Casez, Olivier
    Cohen, Mikael
    Durozard, Pierre
    Demortiere, Sarah
    Giorgi, Laetitia
    Maillart, Elisabeth
    Mathey, Guillaume
    Mazzola, Laure
    Rico, Audrey
    Camdessanche, Jean-Philippe
    Deiva, Kumaran
    Pelletier, Jean
    Audoin, Bertrand
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (02) : 261 - 265
  • [6] Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity
    Rjeily, Nicole Bou
    Fitzgerald, Kathryn C.
    Mowry, Ellen M.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (02) : 257 - 260
  • [7] Ocrelizumab: a new milestone in multiple sclerosis therapy
    Mulero, Patricia
    Midaglia, Luciana
    Montalban, Xavier
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
  • [8] Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients
    Maier, Smaranda
    Hutanu, Adina
    Barcutean, Laura
    Sarmasan, Emanuela
    Balasa, Rodica
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2024, 32 (03): : 245 - 254
  • [9] Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report
    Mahyad, Mahshid
    Baghaei, Mahdieh
    Baghaei, Ava
    Nahayati, Mohammadali
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (12)
  • [10] Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
    Maria Cellerino
    Giacomo Boffa
    Caterina Lapucci
    Francesco Tazza
    Elvira Sbragia
    Elisabetta Mancuso
    Nicolò Bruschi
    Simona Minguzzi
    Federico Ivaldi
    Ilaria Poirè
    Alice Laroni
    Gianluigi Mancardi
    Elisabetta Capello
    Antonio Uccelli
    Giovanni Novi
    Matilde Inglese
    Neurotherapeutics, 2021, 18 : 2579 - 2588